Is Salesforce a buy?
It’s time to talk about one of the most well-known cloud names within the market. Here is the breakdown on $CRM, otherwise known as Salesforce.
Current Price: $219.36
52/Wk High: $284.50
52/Wk Low: $115.29
Market Cap: $202.3 billion
Read below for the breakdown!
Salesforce ($CRM) is a major provider of software for enterprise customers. The majority of the Salesforce offerings use cloud technology and the company operates in a vast array of technology fields.
In recent news, Salesforce announced the acquisition of Slack ($WORK) for a whopping $27.7 billion. The deal consists of both cash and stock and will create a more head-on competition dynamic between Salesforce and Microsoft.
Not only is the deal expected to benefit Salesforce greatly but many experts believe the deal will strengthen Slack and boost Salesforce revenue numbers to new highs.
Breaking down the stock price according to TREFIS (@trefis) data 57.0% of the price is based on Salesforce’s Cloud-Based CRM Software segment.
Furthermore, 38.5% of the stock price is base on the company’s Cloud Software segment, 0.7% is based on their Consulting & Services segment, and 3.8% is based on cash.
Digging into the numbers Salesforce reported another beat, exceeding expectations for Q3 2021. Salesforce beat Q3 EPS expectations of $0.75 with an EPS of $1.74.
Not only that but Salesforce reported revenue growth of 20% year over year, bringing Q3 revenue to a whopping $5.42 billion.
The company also reported the current remaining performance obligations (future revenues under contract) totaled $15.3 billion, representing a 20% increase.
Breaking the Salesforce’s revenues down the subscription and support revenues totaled $5.09 billion (up 20% YOY) and the professional services and other revenues totaled $0.33 billion (up 22% YOY).
Salesforce went on to report that the third quarter non-GAAP operating margin landed at 19.8% and GAAP operating margin landed at 4.1%.
Salesforce management also produced solid guidance for both Q4 and the years ahead. Management expects revenues to total $5.665 billion to $5.675 billion in the fourth quarter, representing a roughly 17% year over year increase.
When it comes to FY 2021, management raised revenue guidance to a range of $21.10 billion to $21.11 billion, representing a roughly 23% increase in revenues year over year.
Salesforce also produced Q1 2022 revenue guidance, noting that Q1 2022 revenues are expected to land within a range of $5.680 billion to $5.715 billion. For FY 2022 revenue guidance as a whole, revenues are expected to land within a range of $25.45 billion to $25.55 billion.
Taking a look at the balance sheet the numbers are quite solid.
Total Debt: $2.672 billion
Total Liabilities: $18.826 billion
Total Assets: $59.136 billion
Cash & Short Term Inv: $9.492 billion
While the numbers are stellar the valuation has gotten a bit extended.
Price to Earnings: 132.87x
Price to Sales: 9.98x
Price to Book: 5.02x
Price to Cash Flow: 28.83x
Management has also been quite effective.
Return on Equity: 4.25%
Return on Assets: 2.87%
Return on Invested Capital: 3.62%
Given the numbers, the analysts remain very bullish on Salesforce ($CRM) with the mean price target sitting at $277.17/share, representing a 26.19% upside.
It is also important to note that the high price target is $320.00/share, representing a 45.69% increase, while the low price target is $217.00/share, representing a -1.20% decline.
On a technical basis, $CRM could be flashing opportunity as well! According to the six-month charts, the MACD has entered a downward momentum run within a range of -6.36 to -8.13.
The six-month charts are also indicating an RSI of 33.80 and CCI of -81.0, both of which are on the low end. It is also important to note that $CRM trades more than 60 points off its highs.
In short, Salesforce is an excellent long term investment given the digital workplace shift, consistent double-digit growth, and an ever-improving product offering.
EAT - SLEEP - PROFIT
Disclaimer: This is not direct financial advice, simply an opinion based on independent research.